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Type IV collagenase i  a metalloproteinase associated with metastatic tumor cells.It specifically cleaves the triple helical 
basement membrane (type IV) collagen molecule at a single site. Monoclonal antibodies which block the activity of the 
human type IV collagenase w re developed and used to purify this antigen. The purified type IV collag nase was partially 
sequenced following cyanogen bromide and trypsin cleavage. The amino acid sequence ofthe human type IV collagenase 
fragments revealed a region homologous to the human interstitial collagenase and stromelysin. However, several sequen- 
ces in type IV collagenase were identified which are distinct from the latfer. Polyclonal antibodies were raised against 
a synthetic peptide derived from such a sequence. Following affinity purification, theantibodies recognized the denatured 
human type IV collagenase in Western immunobiotting. These data indicate that type IV collagenase i  a distinct member 
of a general family of metalloproteinases. 
Type IV collagenase; Metailoproteinase; Basement membrane; Metastasis 
1. INTRODUCTION 
Type IV collagen, a major structural component 
of the basement membrane, is cleaved by a 70 kDa 
type IV collagenase, a metalloproteinase produced 
by invasive tumor cells [1-4]. Type IV collagen is 
resistant to cleavage by interstitial collagenase, 
which degrades collagens I, II, I I I  and X. In con- 
trast, type IV collagenase produces a specific 
cleavage in type IV collagen but does not degrade 
other collagen types or laminin, a major glycopro- 
tein of basement membranes [3,4]. Type IV col- 
lagen monomers are about 350 nm long triple 
helical molecules that contain a noncollagenous 
globular knob at the carboxyl-terminal end. The 
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molecules are thought o form a network structure 
with two individual molecules joined at the 
carboxyl-terminus and four molecules joined at the 
amino-terminus [6]. Type IV collagenase cleaves 
the triple helical molecule approx. 25070 of the 
distance from the amino-terminus in a pepsin resis- 
tant domain [4]. Type IV collagenase has a poten- 
tial, therefore, to disrupt the type IV collagen 
network in the basement membrane that is a pre- 
requisite for cancer invasion and metastasis [2]. 
A previously observed [2,5] biochemical linkage 
of the metastatic phenotype to the secretion of type 
IV collagenase has been supported by studies 
employing rat embryo fibroblasts [7] and NIH 3T3 
cells [8] transfected by the ras oncogene. Transfec- 
tion of c-Ha-ras into the cells produced fully 
metastatic tumor cell clones. In contrast, 
cotransfection of c-Ha-ras with adenovirus 2Ela 
oncogene resulted in fully tumorigenic ells which 
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were not  metastat ic  [9]. A l l  n ine metastat ic  tumor  
c lones in this study produced  high levels o f  type IV 
col lagenase.  However ,  all f ive nonmetasta t i c  
c lones produced  very low or  undetectab le  l vels o f  
this prote inase.  
In order  to study the molecu la r  propert ies  o f  
type IV col lagenase and its re lat ionship to other  
known meta l loprote inases ,  it is necessary to have 
specif ic ant ibodies  which recognize the enzyme,  
alter its act iv ity,  and dist inguish this prote inase 
f rom other  known meta l loprote inases  such as in- 
terstit ial  co l lagenase and st romelys in  [10-12] .  We 
have deve loped monoc lona l  ant ibodies  to the en- 
zyme and immunopur i f ied  and part ia l ly  sequenced 
the ant igen.  The results show that  type IV col-  
lagenase conta ins  sequences related to st romelys in  
and interstit ial  co l lagenase suggest ing that  these 
three enzymes be long to the same fami ly  o f  
meta l loprote inases .  
2. MATERIALS  AND METHODS 
2.1. Purification of antigen and production of monoclonal 
antibodies 
For the preparation f monoclonal antibodies type IV col- 
lagenase was purified from culture media of human melanoma 
cells (A2058, Meloy Laboratories, Springfield, VA) using 
(NH4)zSO4 precipitation, molecular sieve (BioGel A1.5m) and 
affinity chromatography on type IV collagen-Sepharose as 
described elsewhere [3]. Additionally, a DEAE ion-exchange 
chromatography step was used prior to the molecular sieve in- 
stead of concanavalin A-Sepharose. A 6-week-old female 
BALB/c mouse was immunized with the purified antigen (40/zg 
s.c. + 20/zg i.p. + 20/~g i.v.) and the spleen cells were fused 
with mouse myeloma cells NS-1 [13] using the standard pro- 
tocols [14] and plated on 96-well microtiter plates (Flow). 
ELISA and immunoblot assays were performed with the 
same procedure using either Tris- or phosphate-buffered saline. 
The nonspecific binding sites were blocked with 10/0 bovine 
serum albumin, immune antibodies were incubated for 2 h and 
finally horseradish peroxidase conjugated antimouse IgG an- 
tibodies for 1 h at room temperature. The peroxidase reaction 
was visualized using 4-chloro-l-naphthol and H202 as 
substrate. 
2.2. Enzyme purification with a monoclonal antibody 
immunoaffinity column 
Ascites from mice were dialyzed in TBS, pH 8.5 and 
chromatographed on a protein A-Sepharose column (Phar- 
macia) and the bound IgG was eluted with 0.1 M glycine-HCl, 
pH 3.0, dialyzed against 0.5 M NaC1, 0.1 M NaHCO3 and 
coupled to cyanogen bromide-activated Sepharose (Phar- 
macia). The conjugated matrix was washed with 0.05 M Tris- 
HC1, pH 7.4, containing 3.5 M NaSCN to remove nonspecific 
bound proteins. The enzyme was precipitated with 600/0 
saturated ammonium sulphate, dialyzed, applied to the column 
and washed with 0.05 M Tris-HCl, 1.0 M NaCI, 0.01 M CaCI2, 
pH 7.4. The bound enzyme was eluted with 0.05 M Tris-HC1, 
3.5 M NaSCN, pH 7.4. 
2.3. Preparation of antibodies to synthetic peptides 
The synthetic peptides used in the immunization procedures 
were made on a Biosearch 9600 peptide synthesizer. The pep- 
tides were conjugated to bovine serum albumin using 
glutaraldehyde. Two rabbits for each antigen were immunized 
i.d. using complete Freund adjuvant in all immunizations. 
Serum from the fourth bleed onwards was used to prepare lgG. 
This step was carried out by heating the serum first to 56°C for 
0.5 h, and absorbing the pertinent antibody then on the ap- 
propriate peptide-AffiGel 10 resin at 4°C for 18 h with gentle 
agitation. After thorough washing, the absorbed antibody was 
eluted from the resin with 0.1 M acetic acid. The eluate was 
neutralized to pH 7.0 with NaOH, and the resulting solution 
was concentrated and exchanged to PBS (Amicon YM-10 
diaflo). 
2.4. Cell cultures and biosynthetic radiolabeling of tumor cell 
proteins 
Human melanoma (A2058) cells were cultured to confluency 
after which the culture flasks were washed twice with PBS. The 
cells were then grown in serum-free DMEM supplemented with 
250/zCi of [35S]methionine p r flask for two days. The medium 
was collected and the proteins were precipitated with am- 
monium sulphate at 60°'/0 saturation. The precipitate was cen- 
trifuged, the pellet dissolved and dialyzed in the same buffer. 
2.5. Amino acid sequencing 
Trypsin digestion was performed at an enzyme to substrate 
ratio of 1 : 100, 37°C, pH 8.2 for 6 h. Alternatively, the purified 
type IV collagenase protein was digested with cyanogen 
bromide [15], dissolved into 400/zl of 0.10/0 trifluoroacetic 
acid/acetonitrile and chromatographed as two 200/zl injections 
on a reverse-phase Hamilton PRP-I column (25 cm x 4.1 mm) 
with a flow rate of 2 ml/min. Amino acid sequencing of the 
purified fragments was performed on a model 470A gas-phase 
sequencer (Applied Biosystems Inc.) with an attached model 
120A-PTH analyzer using the manufacturer's program 
03RPTH. The sensitivity was 20 pM and the repetitive yield was 
950/0. 
2.6. Other procedures 
SDS-polyacrylamide g l electrophoresis (SDS-PAGE) was 
carried out using 9% separating els and 40/0 stacking els [16] 
or 10-150/0 gradient separating gels on a Pharmacia 
PhastSystem. Gelatin zymogen gels described previously [17]. 
Type IV collagenase activity was measured using [3H]proline- 
labeled type IV collagen as substrate [2,3]. Inhibition of en- 
zymic activity was determined using purified IgG, which was 
added to the reaction mixture before the substrate. 
3. RESULTS 
3.1. Characterization o f  monoclonal antibodies to 
human type IV  collagenase 
The pur i f ied ant igen f rom the melanoma cell 
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line A2058 contained the 68 kDa type IV col- 
lagenase polypeptide described previously [3] and 
additionally another protein of about 100 kDa 
(not shown). Following the immunization pro- 
cedure, the hybrid cells were plated into 360 
microtiter plate wells and tested for production of 
antibodies in an ELISA assay using the same an- 
tigen as for immunization. A total of 17 positive 
cloned hybrids were derived from the primary 
cultures, and the IgG produced by these clones was 
screened for inhibition of type IV collagenase ac- 
tivity (H6yhtyfi et al., in preparation). One an- 
tibody (6B2-A) inhibited the enzyme activity in a 
dose-dependent manner up to 60°70 at 10/zg/ml 
(not shown) whereas control IgG had no effect. 
This antibody did not stain the human enzyme pro- 
tein in Western blots of the SDS-denatured protein 
indicating that it only recognizes the native form of 
the enzyme. This was verified using a dot blot 
assay with native and SDS-treated enzyme where 
only the native protein stained positively (fig. 1). In 
this assay, the antibody detected type IV col- 
lagenase from human melanoma (A2058) and 
human breast carcinoma (MCF-7) cells (fig.2). 
3.2. Immunoaffinity purification of  type IV 
collagenase 
The purified 6B2-A IgG was immobilized on ac- 
tivated Sepharose and used for affinity purifica- 
tion of the type IV collagenase. Cell culture media 
containing the enzyme, secreted by the human 
melanoma A2058 cell line, were applied to the col- 
umn in collagenase buffer and the bound antigen 
eluted with 0.05 M Tris-HCl, 3.5 mM NaSCN, pH 
7.4. As shown in fig.3A, the protein migrated as a 
sinsle 68 kDa band in SDS-PAGE. In vivo labeled 
proteins ecreted by A2058 were applied to the col- 
umn and the bound material was eluted. This pro- 
cedure also resulted in a single-step urification of 
the antigen with an identical migration pattern in 
SDS-PAGE after reduction (fig.3B). 
3.3. Sequence analysis of  human type IV 
collagenase 
Purified preparations of type IV collagenase 
from the human melanoma A2058 and breast car- 
cinoma (MCF-7) ceils that were recognized by the 
specific monoclonal antibody were subjected either 
to cyanogen bromide or trypsin cleavage. The 
resulting peptides were separated by HPLC,  and 
Fig.1. Dot blot analysis showing the reactivity of monoclonal 
anti-type IV collagenase lgG (6B2-A) with the native ( - SDS) 
and denatured (+SDS) enzyme derived from human breast 
carcinoma. 
five were partially sequenced (fig.4A). As seen in 
fig.4B, one of the sequences (TP1) exhibits clear 
homology to human stromelysin and human in- 
Fig.2. Dot blot of human type IV collagenase using a 
monoclonal antibody (dilution 100/~g/ml). Rows: A, purified 
human A2058 melanoma cell type IV collagenase (fig.5, lane 
B); B, purified human ras-transfected MCF-7 type IV 
collagenase; C, crude A2058 metalloproteinase (fig.5, laneA). 
Concentrations: A1, BI, l0 ng; A2, B2, 50 rig; A3, B3, 100 ng; 
A4, B4, 250 ng; column 5, control BSA 250 rig; CI, 100 ng; C2, 
500 ng; C3, 1/zg; C4, 2/~g. 
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Fig.3. lmmunoaffinity purification of human melanoma cell 
(A2058) type IV collagenase. Serum-free cell culture media were 
applied to an IgG-Sepharose column and eluted with 3.5 M 
NaSCN, 0.5 M Tris-HCI, pH 7.4. The eluate was analyzed by 
SDS-PAGE. (A) Unlabeled medium protein. PhastSystem 
gradient gel 10-15%. (B) Analysis of the protein metabolically 
labeled with [35S]methionine using a 9% separating gel. 
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Fig.5. Immunoprecipitation andimmunoblotting of human 
type 1V collagenase using affinity purified rabbitanti-synthetic 
peptide (CB 4) IgG antibodies. Lanes: A-C, gelatin substrate 
gel; D-E, Western immunoblotting; polyacrylamide gel 
electrophoresis without reduction. Molecular sizes in kDa are 
shown on the left. (A) Crude preparation from conditioned 
media of human melanoma A2058 metalloproteinase activity; 
(B) purified type IV collagenase (100 ng) from A2058; (C) 
specific immunoprecipitation of type IV collagenase using 
antisynthetic peptide antibodies. Source material is shown in 
lane A. (D) Immunoblotting of purified A2058 type IV 
collagenase (100 ng antigen), using 100/~g/ml of affinity 
purified anti-peptide antibodies; (E) immunoblot control using 
500/~g/ml of pre-immune IgG. 
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Fig.4. (A) Amino acid sequences of cyanogen bromide (CB)- or 
trypsin (TP)-cleaved peptides of human type IV collagenase. (B)
Sequence homology f the TP 1 peptide with regions of human 
interstitial collagenase (residues 118-136, [ 1, 2]) and human 
stromelysin (residues 118-136 [llD. Identical amino acids are 
shown by boxes and conserved substitutions between type IV 
collagenase and the other enzymes are shown by dots. 
terstitial collagenase [11]. The other sequences 
were unique. Synthetic peptides corresponding to
sequence CB4 were coupled to a lbumin and an- 
tibodies raised in rabbits. The antibodies were 
aff inity-purif ied on columns containing the im- 
mobil ized synthetic peptide. They recognized the 
denatured antigen following SDS-PAGE and im- 
munoblott ing (fig.5). This was the same antigen 
which was recognized in its native state by 6B2-A. 
The antipeptide antibodies are able to recognize it 
as well since they specifically immunoprecipitated 
the type IV collagenase antigen from a 
heterogeneous mixture of metalloproteinases 
secreted by human melanoma cells. The presence 
of gelatin degrading activity of type IV collagenase 
was shown in zymogen gels (fig.5). 
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4. DISCUSSION 
The monoclonal antibody (6B2-A) to human 
melanoma-derived type IV collagenases that are 
characterized in the present study, exhibit in- 
hibitory effect on the activity of the enzyme. 
However, the maximum inhibition was only 60°7o 
of the original activity which indicates that the an- 
tibody does not bind directly to the active site of 
the enzyme. The antibody presumably recognizes a 
conformational epitope because it does not react 
with the SDS-treated enzyme. Conformation 
specificity as opposed to amino acid sequence 
specificity is a common finding for monoclonal n- 
tibodies. The antibody detects type IV collagenase 
from several human tumors. 
The reactivity of the monoclonal ntibody with 
the native nzyme could be utilized for a single step 
purification procedure based on IgG affinity 
chromatography. Both unlabeled and biosyn- 
thetically labeled proteins from culture media of 
human melanoma cells that bound to the anti-type 
IV collagenase IgG column, migrated as a single 
68 kDa band in SDS-PAGE after reduction. This 
demonstrated high binding specificity which en- 
abled quantitative purification of the antigen. 
Previous reports have shown that interstitial col- 
lagenase [12] and stromelysin (transin- 1 [10,11,181) 
as well as a still unidentified related metallopro- 
teinase, protein transin-2 [19] are homologous. 
The highest similarity is present in a region that has 
been identified as the zinc-binding site in the en- 
zyme [11]. This is in keeping with the fact that all 
of these metalloproteinases have EDTA-inhibited 
gelatinase activity. Substrate specificity may be 
related to regions in the metalloproteinases 
separate from the zinc-binding domain. Amino 
acid sequence analysis of peptides from the type IV 
collagenase from A2058 melanoma and ras -  
transfected MCF-7 breast carcinoma cells revealed 
a 19 residue sequence that has homology to both 
human stromelysin and interstitial collagenase. In
this sequence, there are 9 identical residues both in 
human stromelysin and interstitial collagenase and 
5 conservative substitutions. This suggests that 
type IV collagenase belongs to the same family of 
metalloproteinases. 
Polyclonal antibodies made against the CB4 
peptide (fig.4) that does not share homologous se- 
quence with either stromelysin or interstitial col- 
lagenase only recognize the type IV collagenase 
protein. This further confirms that the sequenced 
peptides are derived from the true type IV col- 
lagenase. These unique sequences may play a role 
in the substrate specificity of type IV collagenase. 
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